Your SlideShare is downloading. ×
0
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Pressure BioSciences Investor Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pressure BioSciences Investor Presentation

1,429

Published on

Published in: Investor Relations
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,429
On Slideshare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
1
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Investor PresentationPressure BioSciences, Inc. ( (OTCQB: PBIO) ) Discovery Starts with Sample Preparation™ August 10, 2012 g ,
  • 2. Forward Looking StatementsThisThi presentation may contain f t ti t i forward l ki statements d looking t t t that reflect management’s current views and opinions as to the status of the Company’s products, technology andother future events and operations These statements are operations. neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated Investors indicated.are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the g, , Company’s filings with the Securities and Exchange Commission. 2
  • 3. Key Investment Highlights• Pressure Cycling Technology (PCT): Powerful, Enabling, Patented• $6 Billion M k t O Billi Market Opportunity: Bi l i l Sample Preparation t it Biological S l P ti• Focus on Sample Preparation for Biomarker Discovery & Forensics• PCT Products Offer Si ifi P d t Off Significant Advantages O t Ad t Over Competitive Methods C titi M th d• Proven Technology: ~ 215 Installations in ~150 Marquee Laboratories• E i ti Existing and New Products Offer Significant Growth Opportunity dN P d t Off Si ifi tG th O t it• Attractive “Razor/Razorblade” Business Model• O On-going Discussions with Large Potential Strategic Partners i Di i ith L P t ti l St t i P t• Experienced Management Team and Board of Directors• F Favorable M k t V l ti bl Market Valuation f th I t for the Investor• Commercialization Program Rollout in 2012 3
  • 4. Company Background• Formed Sept 2004 - Sale of Boston Biomedica (BBII) ( )• Started Significant Operations in 2006• OTCQB: PBIO• Twelve (12) Full-time Employees• Strong Management Team and Board of Directors S f• Focused on the Development and Commercialization of PCT-based Instruments and Consumables for the Preparation C C p of Biological Samples for Research Laboratories• Strong IP - 24 Issued PCT Patents with More Pending 4
  • 5. Experienced Senior Management & BoardManagement• Mr. Richard T. Schumacher, President & CEO Boston Bi B t Biomedica (CEO) P di (CEO); Panacos Ph Pharma (President); C t f Bl d (P id t) Center for Blood Research (CBR Labs - Harvard Medical School) -General Manager• Dr. Edmund Y. Ting, Senior Vice President of Engineering Avure Technologies ( g (CSO); Flow Int’l; Grumman Aerospace; MIT (Ph.D.) ); ; p ; ( )• Dr. Alexander V. Lazarev, Vice President of R&D Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)• Dr Nathan P. Lawrence, Vice President of Sales & Marketing Dr. P Lawrence Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)• Mr. Joseph Damasio, Vice President of Finance & Adm. PricewaterhouseCoopers; NEN Life Sciences; Boston College (MBA)Board• Jeffrey N. Peterson, Board Chairman & Nominations Committee Chair• Kevin A. Pollack, Esq., Audit Committee Chair• Vito J. Mangiardi, Compensation Committee Chair• R. Wayne Fritzsche, SAB Member Liaison• Richard T. Schumacher 5
  • 6. Past Accomplishments – CEO and ChairmanCompany Role Top Market Cap OutcomeSchumacherPressure BioSciences (OTCQB: PBIO) Founder, CEO Founder CEO, DirectorBoston Biomedica (Nasdaq BBII) Founder, CEO, Director ~$120 million SoldPanacos Pharma (Nasdaq PANC) Co-Founder, Director ~$650 million SoldTrinity Biotech (Nasdaq TRIB) Founding Group ~$250 million $250 Going StrongCBR Laboratories (Harvard Med) Founding Group N/A N/AFritzsche *Intelligent Medical Imaging Co-Founder, Chairman ~$280 million SoldImmune Response Co-Founder ~$750 million Now OCHT.PKOpexa PhO Pharma (Nasdaq OPXAW) (N d Co-Founder C F d >$25 million $25 illi Sold S ldCytogen Co-Founder >$100 million SoldOcculogix Co-Founder >$50 million Sold * Mr. Fritzsche was also the founder or co-founder of approximately 20 additional companies and has raised more than $120 million for these companies over the years. 6
  • 7. Value Proposition – Sample Prep Market• Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Development of New Diagnostics & Therapeutics• Sample Preparation is Required Prior to Virtually All Analyses• Current Sample Preparation Methods are Highly Inadequate: bottleneck• PCT Offers Many Clear Advantages Over Current Competitive Products• Current Target: Life Sciences Research Market – minimal regulatory• PBI Holds 24 Issued PCT Patents in Multiple Sample Prep Applications• Early Traction…about 200 PCT Systems installed through Q4 2011 y y g• $6 Billion* Market Opportunity for Sample Preparation Products ~ 500K Scientists in ~ 80K Labs WW require some sample preparation** * Strategic Directions Int’l; **The Emmes Group 7
  • 8. Release Important Biomolecules bygy (PCT) Pressure Cycling Technology ( Lysis p y g y Cell y ) 8
  • 9. Sample Input Quality = Sample Result QualityScientific research can be broken down to three key elements:sample preparation, analysis, & data reduction/interpretation “Discovery Starts with Sample Preparation” 9
  • 10. Competitive LandscapeMostly Commodity Products Through Catalogue Sales• Mortar & Pestle• Dounce homogenizer (glass on glass)• Potter-Elvenhjem homogenizer (Teflon on glass)• Enzymatic Digestion• Polytron shearing homogenizers• Blenders• Bead Beating• Sonication• Repeated Freeze/Thaw cycles• French Press (≤ 2000 PSI) 10
  • 11. PCT Sample Preparation SystemBarocycler™ NEP2320 Barocycler™ NEP3229 PULSE Tube MicroTubes PCT-dependent Kits 11
  • 12. Selected Marquee Customers (40 of 150)• Amgen • Thermo Fisher• Biogen • Target Discovery• Lilly y • Battelle Memorial Institute• Novartis • Harvard Medical School• Monsanto • Harvard School of Public Health• BM Squibb • Rockefeller University• Merck • University of New Hampshire y p• Centocor • Barnett Research Inst (NEU)• Takeda Pharmaceuticals • UCLA• Momenta Pharmaceuticals • UC - San Diego• US Army y • UC - Davis• FBI • Lawrence Livermore• Food and Drug Administration • Stanford University• US Department of Agriculture • University of North Texas• National Institutes of Health • Mississippi State• Armed Forces Inst. of Pathology • Montana State• Centers for Disease Control • Lawrence Berkeley• USAMRIID • University of Kentucky• Beth Israel Deaconess Hospital • Florida Int’l University• Burnham Research Institute • UMASS – Boston 12
  • 13. Current PCT Products & Product Pipeline• PCT Sample Preparation System 2012: Aggressive (Barocycler NEP3229 & NEP2320) Commercialization• The PCT Shredder SG3 Just Released• Barocycler HUB440 Just Released• FFPE System – proteins, DNA/RNA 2013• PCT-based HT (48 - 384 well format) 2014• XstreamPCT™ HPLC Digestion System 2014 13
  • 14. PCT Sample Preparation SystemBarocycler™ NEP2320 Barocycler™ NEP3229 PULSE Tube MicroTubes PCT-dependent Kits 14
  • 15. Product Pipeline (2011 Release) The Shredder SG3 Low Shear, Mechanical, Homogenization Device • Long lasting lithium rechargeable batteries • Paddle for convenient pressure setting • Pressure levels: 15, 30, 45 lbs. Force • Uses PCT PULSE and Shredder Tubes • Heavy Duty, Robust Driver 15
  • 16. Product Pipeline (2011 Release) The Barocycler HUB440 High P Hi h Pressure Generator G t • Compact p • Portable • Versatile • Manual or Computer Controlled • Pressures to 58Kpsi State-of-the-Art High Pressure Generator for Multiple Bioscience Applications 16
  • 17. Product Pipeline (2012 Release) The Barocycler NEP-FFPE y • 1 Billion Stored Samples WW • 6x More Non-redundant Proteins from FFPE Aorta Dr. J. Van Eyk, et al., J. Hopkins • 2x More Unique Proteins from FFPE Mouse Liver Dr. C. Fowler, et al., AFIP PCT-enhanced Protein Extraction fromFFormalin-Fixed P li Fi d Paraffin-Embedded (FFPE) S ffi E b dd d l Samples AVAILABLE 2013 17
  • 18. Product Pipeline (2013 Release) XstreamPCT™ Digestion Module Automated, In-line, On-demand PCT-enhanced Digestion A t t d I li O d d PCT h d Di ti • Significantly Reduced Protein Digestion Time • Increased Membrane Protein Recovery • Rapid & Less Costly De-glycosylation • Excellent ReproducibilityThe First Module in PBI’s Extreme PCT (35,000 psi) HPLC Platform AVAILABLE 2014 18
  • 19. Product Pipeline (2013 Release)The Barocycler HT Multiwell (48/96/384) Process 48, 96, or 384 Samples with the •S f Safety • Speed • Quality • Versatility • Reproducibility of PCT For High Throughput PCT-enhanced Biomolecule Extraction & Accelerated Enzymatic Digestion AVAILABLE 2014 19
  • 20. Financial DataHistorical Revenue Data• 2009 $1,200,000• 2010 $1,300,000 $1 300 000• 2011 $1,000,000Selected Data Through March 31, 2012• Cash/Cash Equivalents ~$ 0.2 million• Inventory ~$ 1.0 million• Debt (unsecured) ~$ 0.06 millionSelected Data Through July 13, 2012• Price per Share $0.42• Total Common 10.4 10 4 million• Total Preferred (com equiv) 0.8 million Total Shares OS 11.2 million• Market Cap (Com/Prfd) p( ) $4.7 million $ 20
  • 21. Capitalization Table As of July 13, 2012In CI Common Stock Equivalents (numbers are approximate) St k E i l t ( b i t )Description Number Common Shares Outstanding 10,400,000 Convertible Preferred Stock D 800,000 Total Common Stock Equivalents 11,200,000 Warrants (Weighted Average Strike Price of $1.06) 5,100,000 Stock Options (Weighted Average Strike Price of $2 17) $2.17) 1,700,000 1 700 000 Total Warrants and Options 6,800,000 Total Proceeds from Exercise of Warrants and Options $9,100,000 21
  • 22. PBI Sample Preparation Focus AreasBiomarker Discovery Dr. Andreas Huhmer – Thermo Fisher Scientific …advantages of speed and quality using PCT in mass spec workflow Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, CBER, FDA …improved influenza vaccine quality using PCT in mass spec workflow Dr. Alexander Ivanov – Harvard School of Public Health …improved protein identification using PCT in mass spec workflow improved Dr. Luke Schneider, Target Discovery, Inc. …improved membrane protein recovery in ovarian cancer studies using PCT in mass spec workflowForensics *** Dr. Henry C. Lee, the Henry C. Lee Institute of Forensic Science …evaluation of PCT in the recovery and detection of DNA in difficult forensic samples Dr. Bruce McCord, Florida International University …improved processing of forensic (rape kit) samples using PCT Dr. Bruce Budowle, Health Science Center, University of North Texas …improved detection of DNA in forensic samples using PCTPathology (FFPE Samples) Dr. Jeff Mason and Dr. Carol Fowler, Armed Forces Institute of Pathology ...improved processing of FFPE (histology) samples using pressure Dr. Jennifer Van Eyk, Johns Hopkins School of Medicine …improved recovery of aorta proteins from FFPE samples using PCT 22
  • 23. Professor Wayne Hubbell - UCLA Distinguished Professor of Chemistry & Biochemistry, and Jules Stein Professor at UCLA "Protein flexibility is the new frontier in understanding protein Proteinfunction and regulation. The study of proteins under pressure has great ability to reveal salient features of protein flexibility, and hence provide new insights into p p g protein function and rational drug design. In my opinion, high pressure will play a central role in the discovery process that lies ahead inthe exciting field of protein science, and the PBI hardware will make major contributions to this field.” December 7, 2011 23
  • 24. Dr. Henry C. Lee Professor of Forensic Science and founder of the Forensic Science Program at the University of New Haven; founder of the HC Lee Institute of Forensic Sciences; and former C f Commissioner of Public i i f P bli Safety for the State of Connecticut. “We are excited about this opportunity to collaborate with “Pressure BioSciences to examine the potential applications of their PCT Platform in improving the collection of forensic evidence, evidence particularly DNA in several important areas of DNA,forensics…such collaborations not only provide new, effective technologies for forensic DNA testing of samples that havebeen difficult or unsuitable using today’s standard techniques today s techniques, but can also provide new and more effective ways to reexamine old biological evidence in cold cases.” 24
  • 25. News of Interest - 2012PBI Expands Sales Reach with Distribution Agreements for China, Australia, and OthersPBI Closes First Tranche ($600K) of a $1.2 Million Above-Market Private PlacementPBI Reduces Board of Directors from Eight to Five; Adds Veterans Mangiardi and PollockIronridge BioPharma Invests $500K in PBIO at $1.02/share (no warrants, etc.)PBI’sPBI’ PCT Platform Key to TDI’s Planned Ovarian Cancer Testing Service Pl f K TDI’ Pl dO i C T i S iCollaboration with Dr. Henry C. Lee and the HC Lee Institute of Forensic ScienceDr. W. Hubbell (UCLA) Presents Data Citing Proteomics Enhancement with PCT ubbe (UC ) ese ts ata C t g oteo cs a ce e t t CEuropean Sales Reach Expanded with Distribution Agmt for Benelux CountriesPBI Reports 2011 Financial Results: 22% revenue increase in Q42011 vs. Q42010; 66% revenue increase in 2H2011 vs 1H2011 vs.$800,000 Private Placement Closed – transaction priced at marketSignificant Progress Cited Using PCT in Processing of Sexual Assault SamplesPBI and DIGI Labs Announce Global Co-Marketing/Selling/Development Agreement 25
  • 26. 2012 Potential Drivers• Aggressive Commercialization Program for PCT Products • Expansion of Distribution Network (3 to ~20 countries) • Expansion of PBI Sales (3 to 8) & Marketing (1 to 3) Teams p ( ) g( ) • Expansion of Strategic Partners (2 to 4, at a minimum)• Expected Completion of Significant Funding (up to 2 years cash)• Measurable Progress on FFPE, XstreamPCT, HT Microwell Instruments and Consumables• Continuation of Aggressive IR (Awareness) Campaign• Significant Revenue Run-rate Increase Throughout 2012 Run rate 26
  • 27. Key Investment Highlights• Pressure Cycling Technology (PCT): Powerful, Enabling, Patented• $6 Billion M k t O Billi Market Opportunity: Bi l i l Sample Preparation t it Biological S l P ti• Focus on Sample Preparation for Biomarker Discovery & Forensics• PCT Products Offer Si ifi P d t Off Significant Advantages O t Ad t Over Competitive Methods C titi M th d• Proven Technology: ~ 215 Installations in ~150 Marquee Laboratories• E i ti Existing and New Products Offer Significant Growth Opportunity dN P d t Off Si ifi tG th O t it• Attractive “Razor/Razorblade” Business Model• O On-going Discussions with Large Potential Strategic Partners i Di i ith L P t ti l St t i P t• Experienced Management Team and Board of Directors• F Favorable M k t V l ti bl Market Valuation f th I t for the Investor• Commercialization Program Rollout in 2012 27

×